Regenxbio Inc

+0.59 (+2.51%)
4:11:09 PM EDT: $24.06 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.04B
Current PE14.15
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$62.73 Million
Adjusted EPS-$0.95
See more estimates
10-Day MA$23.28
50-Day MA$22.92
200-Day MA$25.12
See more pivots

Regenxbio Inc Stock, NASDAQ:RGNX

9804 Medical Center Drive, Suite 210, Rockville, Maryland 20850
United States of America
Phone: +1.240.552.8181
Number of Employees: 372


REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.